XML 60 R39.htm IDEA: XBRL DOCUMENT
v3.25.4

Segment Reporting (Tables) | 12 Months Ended
--- | ---
Oct. 31, 2025
Segment Reporting [Abstract] |
Summary of Significant Segment Expenses | The following table summarizes significant segment expenses, other segment items and the measure of segment net loss of the Company's reportable segment for the years ended October 31, 2025 and 2024:
| Year Ended October 31, |
| 2025 |  |  | 2024 |
Research and development expenses: |  |  |  |  |
Chemistry, Manufacturing and Controls(1) | $ | 49,578 |  |  | $ | 11,994 |
Clinical operations(2) |  | 17,915 |  |  |  | 11,036 |
Other research and development expenses(3) |  | 7,052 |  |  |  | 4,598 |
Personnel-related expenses, excluding stock-based compensation |  | 16,653 |  |  |  | 8,893 |
Stock based compensation |  | 3,282 |  |  |  | 1,794 |
Total research and development expenses | $ | 94,480 |  |  | $ | 38,315 |
General and administrative expenses: |  |  |  |  |
Personnel-related expenses, excluding stock-based compensation |  | 10,850 |  |  |  | 8,501 |
Stock based compensation |  | 6,364 |  |  |  | 3,530 |
Other general and administrative expenses(4) |  | 11,471 |  |  |  | 11,951 |
Total general and administrative expenses |  | 28,685 |  |  |  | 23,982 |
Other segment items(5) |  | (5,863 | ) |  |  | (7,155 | )
Net loss | $ | 117,302 |  |  | $ | 55,142 |
(1) External expenses associated with clinical manufacturing of the Company's lead compound, detalimogene. (2) External and internal expenses associated with clinical operations related to research and development of the Company's lead compound, detalimogene. (3) Represents research and development expenses associated with preclinical, medical affairs, regulatory, quality, program management and facility related costs. (4) Represents general and administrative costs associated with external legal fees, facilities, professional fees, and other overhead costs. (5) For the year ended October 31, 2025, other segment items consist of $9.4 million of interest income, $3.0 of interest expense, and $0.6 million of other expense, net. For the year ended October 31, 2024, other segment items consists of $10.4 million of interest income, $2.8 million of interest expense, $0.4 million gain on extinguishment of debt, and $0.1 million other expense, net. Interest income consists of interest income earned on cash equivalents and marketable securities. Interest expense consists of interest expense on our term loan. Other (income) expense, net primarily consists of realized and unrealized gains and losses.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration